52U logo

Hyloris Pharmaceuticals DB:52U Stock Report

Last Price

€11.40

Market Cap

€327.6m

7D

-2.6%

1Y

-10.2%

Updated

29 Apr, 2024

Data

Company Financials +

Hyloris Pharmaceuticals SA

DB:52U Stock Report

Market Cap: €327.6m

52U Stock Overview

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas.

52U fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Hyloris Pharmaceuticals SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hyloris Pharmaceuticals
Historical stock prices
Current Share Price€11.40
52 Week High€13.35
52 Week Low€10.60
Beta0.58
1 Month Change5.56%
3 Month Change-8.80%
1 Year Change-10.24%
3 Year Changen/a
5 Year Changen/a
Change since IPO-29.28%

Recent News & Updates

Recent updates

Shareholder Returns

52UDE PharmaceuticalsDE Market
7D-2.6%1.3%1.1%
1Y-10.2%-28.6%1.9%

Return vs Industry: 52U exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.

Return vs Market: 52U underperformed the German Market which returned 2% over the past year.

Price Volatility

Is 52U's price volatile compared to industry and market?
52U volatility
52U Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 52U has not had significant price volatility in the past 3 months.

Volatility Over Time: 52U's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201242Stijn Van Rompayhyloris.com

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer.

Hyloris Pharmaceuticals SA Fundamentals Summary

How do Hyloris Pharmaceuticals's earnings and revenue compare to its market cap?
52U fundamental statistics
Market cap€327.60m
Earnings (TTM)-€15.76m
Revenue (TTM)€2.81m

116.4x

P/S Ratio

-20.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
52U income statement (TTM)
Revenue€2.81m
Cost of Revenue€93.00k
Gross Profit€2.72m
Other Expenses€18.48m
Earnings-€15.76m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)-0.56
Gross Margin96.70%
Net Profit Margin-560.13%
Debt/Equity Ratio0%

How did 52U perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.